Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Fiscal Year 2021 Revenues Soar on COVID-19 Test Alliance

NEW YORK — Australian diagnostics firm Genetic Technologies on Tuesday reported a surge in revenues for its fiscal year 2021 as it benefited from a recent commercialization deal for its COVID-19 risk test in the US.

For the 12-month period ended June 30, the firm's revenues jumped to A$120,554 ($88,250) from A$9,864 in the previous fiscal year. The company attributed the revenue increase to a three-year deal, signed in March, to commercialize its test for assessing a COVID-19 patient's risk of severe disease in the US with Infinity Biologix.

Genetic Technologies noted that Infinity Biologix last month put a temporary hold on web-based sales of the test after the New York State Department of Health began a review of the emergency use status for all SARS-CoV-2 tests. The review has been completed, however, and the test is expected to become available again shortly.

Genetic Technologies posted a net loss of A$7.1 million, or A$.08 per share, for the fiscal year versus a net loss of A$6.3 million, or A$.15 per share, in fiscal 2020.

R&D spending rose 24 percent to A$3.1 million from A$2.5 million as the firm advanced its pipeline of polygenic risk score tests for various diseases and its gene panel tests for hereditary cancers. SG&A costs, meantime, were up 13 percent to A$5.3 million from A$4.7 million, in part due to higher stock-based compensation expenses.

At the end of June, Genetic Technologies had A$20.9 million in cash and cash equivalents.

Looking ahead, Genetic Technologies said that it expects to see revenue increases in future financial periods, reflecting the impact of its $4 million cash-and-stock acquisition of direct-to-consumer genetic testing company EasyDNA in mid-July.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.